Konica Minolta Adds Ambry Genetics As First Piece Of Precision Medicine Business
The $1bn deal, partly funded by the public/private Innovation Network Corporation of Japan, will create new diagnostic technologies for oncology and drug discovery, and bring a comprehensive genetic-diagnostic portfolio to Japan, among other markets.
You may also be interested in...
Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017
Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.
Number To Know…1 Billion
With a contribution from the Innovation Network Corporation of Japan, Konica Minolta – the Japanese conglomerate better known for its printers and copiers – agreed to pay $1bn for Ambry Genetics as the first part of planned precision medicine platform.
Cardio Catch-Up: Medtronic, Abbott, Ancora Devices Headline ACC, CRT, THT
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations that you may have missed. This edition focuses on clinical trial presentations from three recent conferences: American College of Cardiology in New Orleans, Cardiovascular Research Technologies in Washington, DC, and Technology and Heart Failure Therapeutics in Boston.